TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The investigational Lyme disease vaccine LB6V reduced cases in a phase III trial, but its main evaluable-population analysis did not meet the study’s predefined success threshold. A modified intent-to-treat analysis narrowly met that threshold, while protection appeared to fall by the third season; further development and booster plans remain unclear.
LB6V, an investigational Lyme disease vaccine, did not meet the prespecified statistical success threshold in the primary analysis of a phase III trial, despite an estimated 73.2% vaccine efficacy. A modified intent-to-treat analysis narrowly cleared the threshold, leaving the overall results mixed as researchers weigh the candidate’s potential and the apparent decline in protection over time.
Among participants aged 5 and older in the trial’s evaluable population, four vaccine recipients and 15 placebo recipients developed Lyme disease after the four-dose regimen. The resulting efficacy estimate was 73.2%, with a 95% confidence interval of 15.8% to 93.5%. The study’s predefined criterion required the lower end of that interval to be greater than 20%, so this analysis did not meet the threshold.
In a modified intent-to-treat analysis, efficacy was 74.8%, with a 95% confidence interval of 21.7% to 93.9%, just above the same lower-bound criterion. Paul Auwaerter, MD, of Johns Hopkins University School of Medicine, presented the findings at the IDWeek annual meeting. The report described the study as placebo-controlled and said it enrolled about 9,400 people at elevated risk through work, home environment or leisure activities.
Adverse events were reported in 58.8% of LB6V recipients and 52.6% of placebo recipients. Events considered related to treatment and prompting withdrawal occurred in 0.3% and 0.1%, respectively. Fatigue, headache, muscle and joint pain, and injection-site pain, redness and swelling were more common among vaccine recipients. Newly diagnosed chronic medical conditions were reported at similar rates: 9.6% in the vaccine group and 9.5% in the placebo group.
A Vaccine Without a Clear Pass
The results matter because no Lyme disease vaccine is currently available in the United States, while Lyme disease remains a substantial public health concern. The source report says more than 80,000 cases are reported to the CDC annually and estimates that 476,000 people are treated each year. Those figures use different measures: reported cases and estimated treatment totals.
The efficacy estimates suggest LB6V may reduce illness, but the primary analysis did not satisfy the trial’s preset statistical rule. The modified analysis crossed that line narrowly; it does not erase the primary analysis result. The findings therefore do not establish that the candidate is ready for use or that regulators will consider the evidence sufficient. The reported decline in efficacy by the third season also raises a practical question about how long protection lasts and whether repeat doses would be needed.
Products Worth Considering
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Oral-B iO Series 7 Rechargeable Electric Toothbrush with 2 Brush Heads and Charging Travel Case
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
As an affiliate, we earn on qualifying purchases.
How the VALOR Trial Was Run
LB6V, formerly called VLA15, is an adjuvanted protein-subunit vaccine designed to target six serotypes across four Borrelia species common in Europe and North America. The report describes a mechanism in which vaccinated people pass antibodies to biting ticks, where the antibodies inhibit the bacteria and help prevent transmission. The candidate had generated immune responses and appeared safe in two earlier phase II trials, according to the source report.
The phase III VALOR trial took place in the United States, Canada and five European countries. Participants received four doses at baseline, two months, approximately five to nine months, and about 18 months. The primary efficacy period began 28 days after the fourth dose and continued through the end of the Lyme disease season. The trial followed participants across three seasons, from 2022 through 2025; the median age was 47, and 97% had at least two stated Lyme disease risk factors.
Lyme disease is caused by Borrelia bacteria transmitted through blacklegged tick bites. Symptoms can include fever, headache, fatigue and the characteristic expanding rash known as erythema migrans. Untreated infection can affect joints, the heart and the nervous system. A previous vaccine, LYMErix, was approved by the FDA in 1998 and withdrawn from the market by its manufacturer in 2002 amid side-effect concerns and declining sales, according to the report.
“Overall, I do think this vaccine has the potential to lower the Lyme disease burden.”
— Paul Auwaerter, MD, of Johns Hopkins University School of Medicine, speaking at IDWeek
Protection Beyond Season Two
The report says efficacy fell from 73.2% in the second season after the four-dose vaccination to 18.6% in the third season. The third-season estimate had a 95% confidence interval from -220.0% to 80.4%, a very wide range that does not provide a precise measure of protection. Antibody geometric mean titers for one measured B. burgdorferi antibody also declined, from 1,100.3 to 35.7. The report describes these findings as a parallel decline, but they do not by themselves settle how long protection lasts.
Available details do not establish whether the trial sponsor will seek regulatory approval, conduct additional studies, or revise the dosing schedule. The source also does not provide a full account of the statistical analysis plan or explain why the evaluable and modified intent-to-treat populations produced different threshold outcomes. A possible annual booster was raised by Auwaerter, but the trial results cited here do not establish that schedule as effective or necessary.
Further Data and Dosing Plans
The next steps depend on decisions by the vaccine’s developers and any subsequent regulatory review. The reported results leave open whether additional analysis or trials will be presented, whether a booster strategy will be studied, and what evidence would be required before the vaccine could become available. Researchers may also examine whether antibody measurements can support immunobridging studies, as Auwaerter suggested, but the report does not give a timeline for that work.
For now, LB6V remains an investigational candidate, not an available Lyme vaccine. The primary analysis missed the trial’s preset threshold, while a modified analysis narrowly met it; the significance of that split and the durability of protection will shape how the results are interpreted.
Key Questions
Did the Lyme disease vaccine trial meet its main success threshold?
No, not in the primary evaluable-population analysis. Its 73.2% efficacy estimate had a 95% confidence interval lower bound of 15.8%, below the trial requirement of greater than 20%. A modified intent-to-treat analysis had a lower bound of 21.7% and narrowly met that criterion.
How many Lyme disease cases were reported in the primary analysis?
Among participants aged 5 and older in the evaluable population, four people who received LB6V and 15 who received placebo developed Lyme disease. The report does not provide those figures as totals for every trial participant in all analyses.
Is LB6V available to the public?
No. The report describes LB6V as an investigational vaccine candidate. It does not say that the vaccine has been approved or that a regulatory application has been filed.
Will people need an annual booster?
That is not established. Auwaerter said an annual booster before Lyme season would make sense given the decline seen in later-season results, but the reported trial did not establish an annual schedule as effective or necessary.
What side effects were reported?
Adverse events occurred in 58.8% of vaccine recipients and 52.6% of placebo recipients. Fatigue, headache, muscle and joint pain, and injection-site pain, redness and swelling were more common in the vaccine group. Treatment-related events leading to withdrawal were reported in 0.3% of vaccine recipients and 0.1% of placebo recipients.
Source: medpagetoday.com
